Navigation Links
ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Date:11/10/2010

e in a class by itself.  We think that this new agent has extraordinary potential in treating previously intractable conditions such as the devastating vasculitis seen in autoimmune diseases."

CCX168 Study Results and ANCA-Associated Vasculitis

In Phase I clinical trials CCX168 was safe and well tolerated, with excellent oral bioavailability and dose-proportional exposure increases in human subjects.  Pharmacokinetic and pharmacodynamic data indicated that 30 to 50 mg of CCX168 given orally twice daily in humans results in greater than 90% C5aR coverage in blood at all times, and this is considered optimal for CCX168 evaluation in Phase II trials in vasculitis.

Supporting the Phase I data are results from a mouse model of anti-neutrophil cytoplasmic autoantibody (ANCA) associated glomerulonephritis (GN).  In this study, human C5aR transgenic mice were employed, and ANCA kidney disease was profoundly inhibited by doses of CCX168 that are very similar to those achieved safely in the human Phase I studies.

CCX168 is a highly potent and very selective compound that specifically targets the receptor for the anaphylotoxin designated C5a, a component of the body's complement system and a potent driver of the inflammatory response associated with ANCA-associated vasculitis and other autoimmune disease. In ANCA disease, auto-antibodies lead to the activation and increased adhesiveness of neutrophils to endothelial cells that line the interior surfaces of blood vessels in the kidney and other organs.  These adhering neutrophils accumulate inside the blood vessels and initiate an inflammatory cascade.  Activation of the complement pathway occurs as a consequence, with production of C5a, one of the most potent pro-inflammatory mediators of the complement system.  C5a, through binding to its receptor C5aR, induces expression of additional adhesion molecules and chemotactic factors, thus
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... & Long, P.A.: , Do you, or did ... , Did you purchase your shares before September 10, ... , Did you lose money in your investment in ... your rights? Rigrodsky & Long, P.A. ... MacFall , announces that a complaint has been filed in the ...
(Date:8/28/2014)... BURLINGTON, Mass. , Aug. 28, 2014 /PRNewswire/ ... imaging system market will grow strongly through 2022 ... 6 percent. This will be largely supported by ... which will increase demand for imaging procedures. The ... also allow more facilities to purchase or upgrade ...
(Date:8/28/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... specializes in patented biopharmaceutical, modernized traditional Chinese medicine ... today updates the timeline for the GMP certification ... The Company is scheduled to submit the ... & Drug Administration,s (CFDA) review in the week ...
Breaking Medicine Technology:Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3Indian Diagnostic Imaging System Market Will Grow at 6 Percent Annually Through 2022 2Indian Diagnostic Imaging System Market Will Grow at 6 Percent Annually Through 2022 3TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... Data Presented at the ASCO Cancer Conference, ... 2007 /PRNewswire/,-- The International Myeloma Foundation (IMF)-supporting ... myeloma patients,families, researchers and physicians-today said that ... multi- national clinical trial shows the,combination of ...
... 04, 2007 /PRNewswire/ -- (SEND2PRESS,NEWSWIRE) -- Epeius Biotechnologies ... in medical oncology and a,definitive benchmark in the ... report of its kind, Le Morte du Tumour ... Journal of,Oncology, Vol.30, pp. 1297-1307 -- documents the ...
Cached Medicine Technology:Study Shows Velcade Plus Doxil Improves Survival in Previously,Treated Patients With Multiple Myeloma 2News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 2News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 3
(Date:8/29/2014)... School of Medicine have identified one way the Ebola ... that could lead to new therapies, in research ... & Microbe . , In work performed at Beamline ... researchers developed a detailed map of how a non-pathogenic ... takes signaling molecules in and out of the cell ...
(Date:8/29/2014)... The 8th Annual Paint Columbus Pink® is a series ... Pooch Contest, Light of Life Ceremony, Power in Prayer, Bright ... – all in support of cancer awareness. , Paint Columbus ... Columbus Pink Foam and Obstacle Challenge on Saturday, October 4th, ... Columbus, Georgia 31904. It will be the first foam and ...
(Date:8/29/2014)... Vancouver, BC (PRWEB) August 29, 2014 ... announced that the company will now be selling purse-sized ... in such a way that they can be carried ... are they portable, the purse-sized range at Honey Gifts ... A long battery life and rechargeable batteries are common ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- The West African ... World Health Organization announcing an estimated 500 new cases this ... Most of the new cases arose in Liberia, the U.N. ... also rose sharply, the Associated Press reported. ... and control," according to the WHO report. "The situation is ...
(Date:8/29/2014)... September yoga month was created by ... and its health benefits. To support this Ekhart Yoga ... "Yoga Month Challenge" , This 4 week guided online ... experienced yogis practice yoga regularly from their own home. ... ' is suitable for all levels, and the dynamic ...
Breaking Medicine News(10 mins):Health News:Paint Columbus Pink Cancer Awareness/Kick-Off Meeting for Anyone Interested in Participating 2Health News:Honey Gifts Now Provides Purse Sized Adult Toys in Vancouver 2Health News:Biggest Ever Weekly Rise in Ebola Cases, U.N. Agency Says 2Health News:Biggest Ever Weekly Rise in Ebola Cases, U.N. Agency Says 3Health News:Ekhart Yoga Launches the Yoga Month Challenge 2
... fatigue is often a major problem for cancer ... completing therapy. Researchers at Mayo Clinic ( http://www.mayoclinic.org/oncology-rst/ ... ( http://ncctg.mayo.edu/ ) (NCCTG) recently completed a study ... and found that, while it did not improve ...
... M.D., Ph.D., FASTRO, and William McBride, D.Sc., Ph.D., have ... Oncology,s most prestigious award, the Gold Medal. They will ... during ASTRO,s 52nd Annual Meeting, taking place October 31 ... Medal is bestowed on revered members who have made ...
... ... targeted internet traffic to their websites. The solution is all in the PT Marketing Academy. ... to use WordPress blogs, search engine optimization for Google search, Facebook, Twitter, YouTube, and all ... ...
... Montreal, Quebec June 2, 2010 Baby boomers retiring ... in Canada or the U.S., however, a study suggests retirees ... and from the mainstream of Mexican life. The study, ... presented at the 2010 Congress for the Humanities and Social ...
... current problem is the mission of analytical chemistry, according to ... the University of the Basque Country (UPV/EHU). The group,s name ... these problems - Farmartem: the abbreviation in Spanish of pharmaceuticals, ... Art has been the line of research least worked on ...
... after mastectomy fared better, researchers say , WEDNESDAY, June ... after a mastectomy may influence the odds of breast ... the Catholic University of Louvain (Leuven) in Belgium looked ... in 327 women from one to four years after ...
Cached Medicine News:Health News:Results from a study testing methylphenidate for cancer-related fatigue 2Health News:Results from a study testing methylphenidate for cancer-related fatigue 3Health News:Larson, McBride named 2010 ASTRO Gold Medalists 2Health News:New Online Physical Therapy Marketing Academy Helps Physical Therapists Conquer The Web 2Health News:New Online Physical Therapy Marketing Academy Helps Physical Therapists Conquer The Web 3Health News:New Online Physical Therapy Marketing Academy Helps Physical Therapists Conquer The Web 4Health News:New Online Physical Therapy Marketing Academy Helps Physical Therapists Conquer The Web 5Health News:Retirees in Mexico cut off, study says 2Health News:Basque researchers apply chemistry to restoration of paintings and dating of signatures 2Health News:Basque researchers apply chemistry to restoration of paintings and dating of signatures 3
Suction catheter with thumb valve, two eyes, whistle tip...
Rubber bronchial coude catheter, X-ray opaque, one eye, whistle tip....
... 200 Corneal Topographer is the result of ... leader in product innovation and value, continues ... diagnostic instrumentation. The CT 200 is faster ... and repeatable results. The CT 200 is ...
... The patented, accurate and proven DGH-KOI ... the patented MOD III or Neumann ... perfect RK/AK knife. Once a fine ... time-tested quality are then blended to ...
Medicine Products: